Highest-materiality recent filing
Gain Therapeutics reports Phase 1b extension: GluSph down 81%, 4.8-pt MDS-UPDRS difference
16 of 19 Part 1 participants continued into 9-month extension; all 16 remain on study at Day 150.
Gain Therapeutics Q1 net loss $0.13/sh; Phase 1b biomarker data support GT-02287
Q1 net loss $0.13 per share vs $0.16; R&D $2.8M, G&A $2.6M; cash $16.5M as of March 31, 2026.
Gain Therapeutics FY2025 net loss $20.2M ($0.61/sh); cash $20.8M; Phase 1b data supports GT-02287
Net loss $20.2M ($0.61 per share) vs $20.4M ($0.89) prior year; R&D $10.2M, G&A $8.5M.
Phase 1b: 19 completed Part 1, 16 entered extension; DMC approved continuation without changes.
GT-02287 reduced elevated GluSph in CSF to near-normal levels after 90 days in Phase 1b study.
Gain Therapeutics Reports Q3 2025 Results and Phase 1b Data for GT-02287 in Parkinson's Disease
Completed enrollment of 21 participants in Phase 1b study of GT-02287, surpassing original target of 15.
Gain Therapeutics reports positive Phase 1b data for GT-02287 in Parkinson's disease
GT-02287 safe and well-tolerated after 90 days; no serious adverse events.
Gain Therapeutics prices $7M public offering of common stock and warrants
Offering of 4,501,640 common shares and warrants to purchase 2,250,820 shares at $3.11 per set.
Gain Therapeutics Phase 1b for GT-02287 enrolls 16 patients; biomarker data now expected Q4 2025
Enrollment reached 16 participants (target 15-20) despite 2-month protocol delay.
GT-02287 showed disease-modifying potential in GBA1 and idiopathic Parkinson's disease models, with biomarkers statistically reduced and lasting after drug washout.
Gain Therapeutics reports FY2024 net loss $20.4M; Phase 1b dosing initiated for GT-02287
Net loss of $20.4M ($0.89 EPS) vs $22.3M ($1.71 EPS) in FY2023; revenue not reported.
Gain Therapeutics updates on GT-02287 Phase 1b trial for Parkinson's disease
Phase 1b trial of GT-02287 approved; dosing imminent in Australia, enrolling 15-20 patients with GBA1 or idiopathic PD.
Gain Therapeutics appoints Gene Mack as permanent CEO, Fuggetta as Principal Financial Officer
Gene Mack, interim CEO since June 2024, appointed President and CEO and Board member effective Jan 6, 2025.
Australian ethics approval obtained for Phase 1b trial of GT-02287 in GBA1-PD and idiopathic PD patients.
Gain Therapeutics reports Q3 net loss of $0.17/share; plans Phase 1b start for GT-02287 by year-end
Net loss per share improved to $0.17 from $0.37 in Q3 2023; R&D spend rose to $2.6M.
Gain Therapeutics regains Nasdaq compliance with $50M market value requirement
Received Nasdaq letter on Oct 21, 2024 confirming regained compliance with MVLS Requirement.
GT-02287 rescued motor and cognitive deficits in GBA1 and idiopathic PD models; effects persisted >1 week after drug withdrawal.
Gain Therapeutics (GANX) enters $50M at-the-market equity offering with Oppenheimer
Equity Distribution Agreement allows sale of up to $50M in common stock via Oppenheimer as agent.
Gain Therapeutics Q2 net loss $0.42/shr; expects MAD Phase 1 topline for GT-02287 in August 2024
Net loss per share $0.42 for Q2 2024 vs $0.62 in Q2 2023; cash & securities $16.9M as of June 30, 2024.
Gain Therapeutics receives Nasdaq MVLS deficiency notice; must regain compliance by Jan 7, 2025
Nasdaq notified Gain on June 11, 2024, that MVLS was below $50M minimum required for Global Market listing.
Completed dosing in MAD part of Phase 1 study of GT-02287 for Parkinson's disease; no discontinuations or serious adverse events.
Gain Therapeutics prices $11M public offering of common stock and pre-funded warrants
Offering of 7,116,547 shares at $1.35/share and 1,031,602 pre-funded warrants at $1.3499 each.
Gain Therapeutics Q1 net loss $0.22/shr; cash $12.7M; GT-02287 Phase 1 SAD positive
GAAP net loss per share $0.22 (Q1 2024) vs $0.43 (Q1 2023); narrower loss.
Gain Therapeutics reports FY2023 net loss of $22.3M; cash runway into Q1 2025
Net loss for FY2023 was $22.3M ($1.71 per share), vs $17.6M ($1.48) in FY2022.
Gain Therapeutics CEO provides operational update; Phase 1 trial advancing, cash runway into 2025
Phase 1 SAD/MAD trial of GT-02287 underway; MAD cohort expected to start Q1 2024, completion by mid-2024.
Public offering of 2,213,044 shares and 1,106,522 warrants at $2.005/unit; warrants exercisable at $2.75 for 5 years.
Gain Therapeutics Q3 net loss $4.7M; Phase 1 trial of GT-02287 underway
Net loss $4.7M ($0.37/sh) vs $4.6M ($0.38/sh) in Q3 2022; R&D expense rose $0.4M to $2.4M.
Gain Therapeutics Q2 net loss $7.7M; Phase 1 trial submission for GT-02287
Net loss $7.7M ($0.62/share) vs $5.1M ($0.43) in Q2 2022, driven by higher R&D and G&A costs.
Gain Therapeutics CFO Salvatore Calabrese departs; severance includes pay and equity acceleration
CFO Salvatore Calabrese terminates April 30, 2023; severance includes €249,827 (12 months' salary) and €41,638 bonus.
Gain Therapeutics appoints C. Evan Ballantyne as CFO, effective April 10, 2023
Appointment: C. Evan Ballantyne named CFO effective April 10, 2023; predecessor Salvatore Calabrese transitions.
Net loss $17.6M ($1.48/share) vs $13.9M ($1.37) in 2021; R&D spend $8.4M, G&A $9.5M.
Net loss of $4.56M ($0.38 per share) vs $4.66M ($0.39) in Q3 2021.
Gain Therapeutics appoints Matthias Alder as CEO; Eric Richman resigns effective Sept 20, 2022
Eric Richman resigned as CEO effective Sept 20, 2022; will remain on board through 2023 annual meeting and serve as senior advisor.
announced that Gene Mack has been appointed the Company’s President and Chief Executive Officer and a member of the Company’s board of directors (the “Board of Directors”), effective January 6, 2025.
On June 27, 2024, Mr. Gene Mack (“Mr. Mack”), the Company’s current Chief Financial Officer, was appointed to serve as Interim Chief Executive Officer (“Interim CEO”), effective as June 25, 2024, to fill the vacancy created by Mr. Alder’s departure as Chief Executive Officer.
On June 25, 2024, Matthias Alder (“Mr. Alder”), Chief Executive Officer of Gain Therapeutics, Inc. (the “Company”), and the Company mutually agreed that his service as Chief Executive Officer of the Company would terminate so that Mr. Alder can pursue other opportunities.
On June 27, 2024, Dr. Khalid Islam (“Dr. Islam”), the current Chairman of the Board, was appointed to serve as Executive Chairman of the Board, effective June 25, 2024.
On April 5, 2024, Gain Therapeutics, Inc. (the “Company”) appointed Gene Mack as its Chief Financial Officer, to be effective as of April 8, 2024
Upon Mr. Mack’s appointment, Gianluca Fuggetta, who had been serving as the Company’s Principal Financial Officer since March 1, 2024, will no longer serve in that capacity and will continue in his role as the Company’s Vice President of Finance and Principal Accounting Officer.
On February 19, 2024, Gain Therapeutics, Inc. (the “Company”) received notice of the resignation of C. Evan Ballantyne as the Company’s Chief Financial Officer, and all other positions held at the Company, to be effective March 1, 2024.
On February 21, 2024, the Board of Directors of the Company appointed Gianluca Fuggetta, the Company’s current Senior Director, Finance & Corporate Reporting and Principal Accounting Officer, as the Company’s Vice President of Finance and to also serve as the Company’s Principal Financial Officer, to be effective March 1, 2024.
Mr. Calabrese’s employment terminates effective April 30, 2023
the Company informed Salvatore Calabrese, the Company’s former Chief Financial Officer, that his service as Chief Financial Officer of the Company would terminate effective as of the Transition Date.
announced the appointment of C. Evan Ballantyne as its Chief Financial Officer, effective as of April 10, 2023
The Company’s Chief Financial Officer, Salvatore Calabrese, who was previously serving as both Principal Financial Officer and Principal Accounting Officer, will continue serving as the Company's Principal Financial Officer.
Max materiality 0.80 · Median 0.60 · Most common event other_material